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Background: Sirolimus-eluting stents (SES) show reduced target vessel failure and decreased frequency of TLR compared with bare-metal 
counterparts. This analysis evaluates angiographic profiles of patients receiving SES who undergo late (>1 year) TLR.
Methods: With SIRIUS Trial outcome data available to seven years, a post hoc analysis was performed on QCA data from the Angiographic Core Lab 
in patients requiring TLR after one year following index procedure with SES.
Results: Between one and seven years, 34 patients (6.4%) with SES required TLR (BMS 5.7%, n=30), with events distributed evenly across the 
6 year period. (Cumulative 7 year TLR rates were 12.2% SES vs 26.5% BMS). A statistically significant difference is seen comparing percentage 
diameter stenosis (% DS) and MLD in the ‘in-stent’ and ‘in-lesion’ segments of SES group immediately post PCI (both p<0.0001). This discrepancy 
between the disease within the stent and that at stent edge persists at all time-points, and at time of TLR a similar difference is seen comparing 
the % DS in the ‘in-stent’ and ‘in-lesion’ segments (48+/-33.8% vs 69.4+/-22.35%, p<0.0001). 44.6% (n=29) of SES group have type 1B in-stent 
restenosis (focal stent edge).
Conclusions: Intimal hyperplasia within the stent is an uncommon cause of late restenosis, and a stent edge discrepancy that arises immediately 
following stent deployment persists at all time-points. Restenosis at stent edge subsequently leads to TLR requirement, and this risk persists over 
long-term follow-up.
 
